Westminster, CA – November 20, 2018 – BioLargo, Inc. (OTCQB:BLGO),
developer of sustainable science and technologies and a full-service
environmental engineering company, today announced the completion of a third-party study indicating
the company’s Advanced Oxidation System (AOS) water treatment technology can
eliminate certain toxic micropollutant contaminants associated with municipal
wastewater. Micropollutants are widespread and persistent contaminants of
significant concern to regulators due to environmental and human health
concerns, and are difficult to treat using conventional wastewater treatment
technologies (such as UV and biological treatment).
Consequently, discharge of
micropollutants in municipal wastewater effluents is currently a high priority issue
for regulators and municipalities. Due to the lack of existing economically
viable solutions for the elimination of micropollutants from municipal
wastewater, these findings make the AOS a breakthrough in advanced municipal wastewater
treatment.
BioLargo had previously reported on a third-party study
conducted in collaboration with researchers at the Centre Des Technologies de
L’Eau suggesting its AOS technology effectively removes certain pharmaceutical
by-products (i.e., micropollutants) from water (Link
here).
In this follow-up study conducted by Dr. Greg Goss, an
expert in aquatic toxicology at the University of Alberta, in collaboration
with BioLargo’s Canadian subsidiary BioLargo Water, Inc., Dr. Goss examined the
environmental safety of AOS-treated municipal wastewater to demonstrate it did
not produce toxic by-products, and whether the AOS’ ability to eliminate
pharmaceuticals from water would improve the environmental safety and water
quality of municipal wastewater “spiked” with high concentrations of
micropollutant contaminants of particular concern to regulators.
This study succeeded on both fronts, demonstrating that
water treated by the AOS technology was non-toxic to certain aquatic organisms typically
used for testing whole effluent toxicity for the EPA’s National Pollutant
Discharge Elimination System (NPDES) Permits Program, such as Daphnia and rainbow trout, as well as zebrafish
embryos. Additionally, the AOS eliminated biomarker responses of municipal
wastewater that has been experimentally contaminated (spiked) with compounds
(benzo[a]pyrene and 17β-estradiol) known to negatively affect those organisms.
Further, the study showed that the AOS reduces the
well-documented aberrant endocrine disrupting chemical (EDC) effects of
17β-estradiol (an estrogen derivative) on rainbow trout. AOS was able to reduce
both the normal EDC effects of municipal wastewater on rainbow trout and was
also successful in removing 17β-estradiol from municipal wastewater spiked with
much higher levels of the hormone.
These results represent promising evidence that the AOS can
remove micropollutants that are an emerging concern to the water treatment
industry. Given that micropollutants are bioactive and persistent contaminants that
are not removed by traditional wastewater treatment methods, AOS has the
potential to fill an important niche treatment gap with growing demand: effective
and cost-efficient removal of micropollutants in wastewater treatment.
Dr. Greg Goss commented on the results, “More work is needed,
but it appears that the AOS treatment is a major technical breakthrough for the
removal of micropollutants from wastewater.”
This work was funded in part by the Canadian Natural Science
and Engineering Research Council (NSERC) and the National Research Council of
Canada Industrial Research Assistance Program (NRC IRAP).
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and
environmental engineering company driven by a mission to "make life
better" by delivering robust, sustainable solutions for a broad range of
industries and applications, with a focus on clean water, clean air, and
advanced wound care. We develop and commercialize disruptive technologies by
providing the capital, support, and expertise to expedite them from
"cradle" to "maturity" (www.biolargo.com). Our engineering
division features experienced professional engineers dedicated to integrity,
reliability, and environmental stewardship (www.biolargoengineering.com).
Our industrial odor control division, Odor-No-More (www.odornomore.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates
the odor-causing compounds and VOCs rather than masking them, and is now
winning over leading companies in the solid waste handling and wastewater
industries and other industries that contend with malodors and VOCs. Our
subsidiary BioLargo Water (www.biolargowater.ca) develops
the Advanced Oxidation System "AOS," a disruptive industrial water
treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com)
features effective and gentle solutions for chronic infected wounds to promote
infection control and regenerative tissue therapy.
Contact Information
Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540
x2
Safe Harbor Act
This press release includes “forward-looking statements”
within the meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Actual results may differ from
expectations, estimates and projections and, consequently, you should not rely
on these forward-looking statements as predictions of future events. Words such
as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,”
“intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,”
“potential,” “continue,” and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements involve
significant risks and uncertainties that could cause the actual results to
differ materially from the expected results.
No comments:
Post a Comment